Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Less than $10/month! Get more Watchlists, Portfolios, Custom Views and Chart Templates with Barchart Plus. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Briacell Therapeutics Corp (BCT.TO)

Briacell Therapeutics Corp (BCT.TO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [TSX]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Profile for [[ item.sessionDateDisplayLong ]]

Company Info

Briacell Therapeutics Corp 235-15th Street Suite 300, 3rd Floor, Bellevue Centre Vancouver BC V7T 2X1 CAN

https://www.briacell.com P: 888-485-6340 F: 424-245-3719

Sector:

Medical

Description:

BriaCell Therapeutics Corp is a clinical-stage biotechnology company focused on developing immunotherapies for cancer treatment, particularly breast cancer. The company's targeted immunotherapy program, Bria-IMT, is a targeted cell-based immunotherapy in end-stage clinical trials aiming to improve outcomes for patients with breast cancer. BriaCell also develops Bria-OTS, personalized off-the-shelf immunotherapies for breast and prostate cancer. BriaCell is involved in clinical collaborations to explore combination therapies for enhanced cancer treatment options.

Key Statistics

Overview:

Market Capitalization, $K 23,568
Shares Outstanding, K 1,884
Annual Sales, $ 0 K
Annual Net Income, $ -26,312 K
Last Quarter Sales, $ 0 K
Last Quarter Net Income, $ -8,198 K
60-Month Beta 3.28
% of Institutional Shareholders 0.01%

Growth:

1-Year Return -90.19%
3-Year Return -98.67%
5-Year Return -98.51%
5-Year Revenue Growth 0.00%

Per-Share Information:

Most Recent Earnings -4.35 on 12/11/25
Next Earnings Date 12/15/25
Earnings Per Share ttm -33.87
EPS Growth vs. Prev Year -63.79%
Dividend Payout Ratio 0.00%
Most Recent Split 1-10 on 08/26/25

BCT.TO Ratios

Ratio
Price/Earnings ttm N/A
Price/Earnings forward N/A
Price/Earnings to Growth N/A
Return-on-Equity % -409.50%
Return-on-Assets % -244.43%
Profit Margin % 0.00%
Debt/Equity N/A
Price/Sales N/A
Price/Book 1.71
Book Value/Share 7.30
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar